Article
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2016
Carter C A, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle L A, Steinberg S M, Xi L, Raffeld M, Tomita Y, Lee M J, Lee S, Trepel J B, Reckamp K L, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G
Abstract excerpt
BACKGROUND: KRAS mutations in NSCLC are associated with a lack of response to epidermal growth factor receptor inhibitors. Selumetinib (AZD6244; ARRY-142886) is an oral selective MEK kinase inhibitor of the Ras/Raf/MEK/ERK pathway. PATIENTS AND METHODS: Advanced nonsmall-cell lung cancer (NSCLC) patients failing one to two prior regimens underwent KRAS profiling. KRAS wild-type patients were randomized to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.